<DOC>
	<DOCNO>NCT02247739</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy recombinant human C1 inhibitor ( rhC1INH ) prophylaxis angioedema attack patient HAE Secondary Objective : To evaluate safety immunogenicity recombinant human C1 inhibitor ( rhC1INH ) prophylaxis angioedema attack patient HAE</brief_summary>
	<brief_title>A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor</brief_title>
	<detailed_description>Study Design : This multi-center , randomize , double-blind , placebo-controlled , 3-period crossover study rhC1INH prophylaxis angioedema attack patient HAE . Medical screening ( clinical laboratory parameter ) perform patient medical history specific HAE attack collect assess eligibility . Each patient receive three 4 week period treatment twice weekly .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Patients fulfil follow criterion Screening eligible participation study : 1 . Age 13 year old 2 . Laboratory confirm diagnosis HAE 3 . A history frequent HAE attack ( least 4 attack per month across minimum 3 consecutive month ) . 4 . Female patient childbearing potential sexually active must willing use acceptable form contraception . 5 . Provided write informed consent ( write assent minor ) 6 . Willingness ability comply protocol procedures Patients meet follow criterion Screening exclude study participation : 1 . Patients medical history allergy rabbit rabbitderived product ( include rhC1INH ) 2 . Diagnosis acquire angioedema ( AAE ) 3 . Patients pregnant , breastfeeding , currently intend become pregnant 4 . Treatment investigational drug past 30 day 5 . Patients condition treatment , opinion Investigator , might interfere evaluation study objectives 6 . Patients currently treat angiotensinconverting enzyme ( ACE ) inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HAE</keyword>
	<keyword>Hereditary Angioedema</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>